ClinicalTrials.gg
RecruitingNCT07375433HIPSTERUpdated Feb 10, 2026

Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course and Prognosis

An observational study in COPD (Chronic Obstructive Pulmonary Disease) and Heart Failure With Preserved Ejection Fraction (HFpEF; Diagnosis), sponsored by National Medical Research Center for Therapy and Preventive Medicine. Recruiting at 2 sites in Russia. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by National Medical Research Center for Therapy and Preventive Medicine · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
200
Ages
50 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Pulmonary Disease, Chronic Obstructive with a site in Russia — 3 open to participants now, 3 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Russia.

Started
2026
with 1 other
Observational
6 of 14
3 open now
Registered
13th of 14
by date
Lead sponsor
1 of 14
National Medical Research Center for Therapy and Preventive Medicine

Among the 14 studies in Pulmonary Disease, Chronic Obstructive with a site in Russia, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 13th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 14 studies in Pulmonary Disease, Chronic Obstructive with a site in Russia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 50 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Pulmonary Disease, Chronic Obstructive with a site in Russia, or all of them as a file.
02

Study summary

Study aim is comparison of heart failire with preserved ejection fraction (HFpEF) detection rate in patients with Сhronic Obstructive Pulmonary Disease (COPD) and the clinical course and prognosis in patients with COPD depending on HFpEF presence.

Read the detailed description

Study aim of Investigation "Heart Failure with Preserved Ejection Fraction in Patients with Сhronic Obstructive Pulmonary Disease: Clinical Course and Prognosis" (HIPSTER) is comparison of heart failire with preserved ejection fraction (HFpEF) detection rate in patients with Сhronic Obstructive Pulmonary Disease (COPD) and the clinical course and prognosis in patients with COPD depending on HFpEF presence.

It is assumed that newly diagnosed HFpEF will occur in at least 6% (COPD PRIORITY data) of cases, and, the presence of HFpEF will negatively affect both the manifestations of the disease and the outcomes and prognosis

During the study it is planned to:

  1. Perform a retrospective analysis of patient records, determine the frequency of intracardiac hemodynamic disorders, corresponding with the criteria for HFpEF and compare them with the diagnosis in clinical records.
  2. Identify the patients with previously undiagnosed HFpEF among patients with COPD, and evaluate the frequency of cardiorespiratory comorbidity.
  3. Examine the general clinical and biochemical blood test parameters in the study groups (as part of a routine in-patient examination).
  4. Evaluate echocardiography parameters in the study groups (as part of a routine protocol + epicardial adipose tissue thickness (EAT), E/e', interventricular septum thickness, left ventricular posterior wall thickness, and end-diastolic dimension (EDD).
  5. Compare spirometry and body plethysmography parameters in the groups depending on the presence of HFpEF criteria.
  6. Compare the functional status (Six-Minute Walk Test, 6MWT) in the study groups.
  7. Evaluate patient's vital status after 12 months, information about hospitalizations and their reasons.
03

Conditions studied

  • COPD (Chronic Obstructive Pulmonary Disease)
  • Heart Failure With Preserved Ejection Fraction (HFpEF; Diagnosis)

Keywords

  • Heart failure
  • Heart failure with Preserved Ejection Fraction
  • Biomarkers
  • COPD
  • Prognosis
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Generic russian population

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Verified diagnosis of ;
  2. Patients hospitalized with COPD;
  3. Citizenship of the Russian Federation;
  4. Patients aged 50 to 70 years;
  5. Patient consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Lack of Russian Federaion citizenship;
  2. Patient's refusal to participate in the study;
  3. Any chronic diseases, other than , that affect the prognosis, in the acute and/or decompensated stage;
  4. Mental disorders.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Сhronic Obstructive Pulmonary Disease

    Patients hospitalized with a verified diagnosis of COPD. Patients with a confirmed diagnosis in accordance with instrumental and clinical criteria.

    Diagnostic Test: Echocardiography · Diagnostic Test: Spirometry · Diagnostic Test: Body plethysmography · Diagnostic Test: 6-Minute Walk Test (6MWT) · Diagnostic Test: laboratory biomarker analysis

Interventions

  • Diagnostic testEchocardiography

    Transthoracic echocardiography at rest: with determination of epicardial fat tissue thickness, epicardial adipose tissue thickness (EAT), E/e', interventricular septum thickness, left ventricular posterior wall thickness, and end-diastolic dimension

  • Diagnostic testSpirometry

    Spirometry is the most common of the pulmonary function tests, which measures the lung capacity and airway patency (volume and speed of air) during quiet and forced breathing.

  • Diagnostic testBody plethysmography

    Body plethysmography is a non-invasive lung function test performed in a sealed booth (body box) that measures total lung volume, functional residual capacity, and airway resistance by using Boyle's Law to track pressure and volume changes as a patient breathes, providing crucial data for diagnosing conditions like COPD and asthma, and differentiating them from other lung disorders

  • Diagnostic test6-Minute Walk Test (6MWT)

    The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity

  • Diagnostic testlaboratory biomarker analysis

    Routine and special laboratory tests

06

What researchers measure

Primary outcomes

  1. Primary composite endpoin

    Primary composite endpoint: all-cause death, rehospitalizations, major adverse cardiovascular events (MACE)

    Time frame: 1 year

07

Study locations

2 of 2 sites recruiting
  • Kazan State Medical University
    Kazan', Russia
    Recruiting
    • Diana I Abdulganieva, MD, professor · Contactdiana.abdulganieva@kazangmu.ru · +78432360922
    • Elina R Kirillova, PhD, Associate Professor · Sub investigator
    • Nailya G Shamsutdinova, PhD, Associate Professor · Sub investigator
    • Diana I Abdulganieva, MD, professor · Principal investigator
  • National Medical Research Center for Therapy and Preventive Medicine
    Moscow, Russia
    Recruiting
    • Olga N. Dzhioeva, MD, Associate Professor · Contactodzhioeva@gnicpm.ru · +79166141821
    • Yriy S Timofeev, PhD · Sub investigator
    • Elizaveta A. Rogozhkina, PhD · Sub investigator
    • Olga N Dzhioeva, PhD, Associate Professor · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 11 months is below that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Jan 29, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07375433
Lead sponsor
National Medical Research Center for Therapy and Preventive Medicine
Collaborators
Kazan State Medical University
Responsible party
Sponsor
First posted
Jan 29, 2026
Start date
Jan 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 10, 2026

Study contacts

Yury S Timofeev, PhD
Contact
Timofeev_lab@mail.ru
+79150104788
Olga D Dzhioeva, MD, associate professor
study director · National Medical Research Center for Therapy and Preventive Medicine
Diana I Abdulganieva, MD, professor
study director · Kazan State Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion